MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 07-29-2025
Country |
 USA |
IPO year |
- |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBALSPB |
Shares |
207 M |
Market Cap[1] |
$ 20.1 B |
EBITDA (LTM) |
$ 573 M |
P/E (LTM) |
66.66 |
P/S (LTM) |
4.41 |
EPS (LTM) |
1.42 |
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
 |
Aptorum Group Limited
APM
|
$ 1.3 | - | $ 7.09 M | Nasdaq Global Select Market |  China |
 |
Arbutus Biopharma Corporation
ABUS
|
$ 5.01 | 6.26 % | $ 831 M | Nasdaq Global Select Market |  Canada |
 |
MorphoSys AG
MOR
|
- | 2.43 % | $ 254 M | Nasdaq Global Select Market |  Germany |
 |
Aclaris Therapeutics
ACRS
|
$ 3.26 | 0.31 % | $ 252 M | Nasdaq Global Select Market | USA |
 |
AlloVir
ALVR
|
- | 4.14 % | $ 49.1 M | Nasdaq Global Select Market | USA |
 |
Aptevo Therapeutics
APVO
|
$ 1.06 | -6.19 % | $ 293 K | Nasdaq Capital Market | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
- | - | $ 40.3 B | Nasdaq Global Select Market | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
$ 0.27 | -3.93 % | $ 588 M | NYSE American |  Israel |
 |
Catalyst Biosciences
CBIO
|
$ 13.88 | -1.53 % | $ 914 M | Nasdaq Capital Market | USA |
 |
Ascendis Pharma A/S
ASND
|
$ 221.31 | 0.4 % | $ 5 B | Nasdaq Global Select Market |  Danmark |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
- | -1.52 % | $ 24.7 M | Nasdaq Capital Market | USA |
 |
Midatech Pharma plc
MTP
|
- | -18.52 % | $ 27.3 M | Nasdaq Global Select Market |  Britain |
 |
Alterity Therapeutics Limited
ATHE
|
$ 3.18 | -2.93 % | $ 7.65 B | Nasdaq Capital Market |  Australia |
 |
Catalyst Pharmaceuticals
CPRX
|
$ 24.01 | 1.65 % | $ 2.84 B | Nasdaq Capital Market | USA |
 |
Biophytis SA
BPTS
|
- | -13.47 % | $ 169 M | Nasdaq Capital Market |  France |
 |
CorMedix
CRMD
|
$ 11.08 | -3.57 % | $ 564 M | Nasdaq Global Market | USA |
 |
CRISPR Therapeutics AG
CRSP
|
$ 57.6 | 1.62 % | $ 4.86 B | Nasdaq Global Market,SPB |  Schweiz |
 |
Институт стволовых клеток человека
ISKJ
|
- | - | - | MOEX |  Russia |
 |
BioVie
BIVI
|
$ 1.39 | -4.03 % | $ 2.05 M | Nasdaq Capital Market | USA |
 |
ARCA biopharma
ABIO
|
- | 1052.0 % | $ 415 M | Nasdaq Capital Market | USA |
 |
Acasti Pharma
ACST
|
- | 4.01 % | $ 150 M | Nasdaq Capital Market | Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
- | -15.15 % | $ 60.3 M | Nasdaq Global Select Market | Britain |
 |
BioNTech SE
BNTX
|
$ 94.09 | -0.76 % | $ 27.2 B | Nasdaq Global Select Market | Germany |
 |
Aeglea BioTherapeutics
AGLE
|
- | - | $ 1.01 B | Nasdaq Global Market | USA |
 |
Albireo Pharma
ALBO
|
- | -0.23 % | $ 916 M | Nasdaq Capital Market | USA |
 |
Alpine Immune Sciences
ALPN
|
- | - | $ 2.17 B | Nasdaq Global Market | USA |
 |
Ampio Pharmaceuticals
AMPE
|
- | -11.43 % | $ 502 K | NYSE American | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
$ 26.23 | 3.8 % | $ 1.27 B | Nasdaq Global Select Market | USA |
 |
Dynavax Technologies Corporation
DVAX
|
$ 10.87 | 0.65 % | $ 1.41 B | Nasdaq Capital Market | USA |
 |
Applied Molecular Transport
AMTI
|
- | - | $ 10.1 M | Nasdaq Global Select Market,SPB | USA |
 |
Anika Therapeutics
ANIK
|
$ 9.57 | 0.05 % | $ 140 M | Nasdaq Global Select Market,SPB | USA |
 |
Eton Pharmaceuticals
ETON
|
$ 16.36 | -2.07 % | $ 420 M | Nasdaq Global Market | USA |
 |
Exelixis
EXEL
|
$ 41.5 | 1.5 % | $ 12 B | Nasdaq Global Select Market,SPB | USA |
 |
Arena Pharmaceuticals
ARNA
|
- | -6.81 % | $ 3.04 B | Nasdaq Global Select Market,SPB | USA |
 |
Athersys
ATHX
|
- | 3.77 % | $ 22.4 M | Nasdaq Capital Market | USA |
 |
Acer Therapeutics
ACER
|
- | 2.71 % | $ 14 M | Nasdaq Capital Market | USA |
 |
Avenue Therapeutics
ATXI
|
- | -52.27 % | $ 4.45 M | Nasdaq Global Select Market | USA |
|
Foghorn Therapeutics
FHTX
|
$ 4.48 | 0.82 % | $ 246 M | Nasdaq Global Market | USA |
 |
AVROBIO
AVRO
|
- | 1083.1 % | $ 745 M | Nasdaq Global Select Market | USA |
 |
Axon Enterprise
AXON
|
$ 551.02 | -2.35 % | $ 41.7 B | Nasdaq Global Select Market,SPB | USA |
 |
Ayala Pharmaceuticals
AYLA
|
- | - | $ 7.46 M | Nasdaq Global Market | Israel |
 |
Aytu BioScience
AYTU
|
$ 2.37 | 3.04 % | $ 14.9 M | Nasdaq Capital Market | USA |
 |
AstraZeneca PLC
AZN
|
$ 91.14 | 1.46 % | $ 96.9 B | Nasdaq Global Select Market | Britain |
 |
Acorda Therapeutics
ACOR
|
- | -24.86 % | $ 820 K | Nasdaq Global Select Market | USA |
 |
Brickell Biotech
BBI
|
- | -5.38 % | $ 6.06 M | Nasdaq Capital Market | USA |
 |
Burford Capital Limited
BUR
|
$ 8.88 | -1.33 % | $ 1.46 B | NYSE | Britain |
 |
BeiGene, Ltd.
BGNE
|
- | 0.49 % | $ 251 B | Nasdaq Global Select Market |  Cayman-islands |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
$ 11.43 | -0.87 % | $ 739 M | NYSE | USA |
 |
Biogen
BIIB
|
$ 173.99 | -0.06 % | $ 25.3 B | Nasdaq Global Select Market,SPB | USA |
 |
Abeona Therapeutics
ABEO
|
$ 5.13 | -4.38 % | $ 110 M | Nasdaq Capital Market | USA |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.